— Webcast of presentation at upcoming investor conference also
announced —
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) antibody-drug conjugate technology, today
announced that the Company will host a conference call at 8:00 a.m. ET
on Friday, August 2, 2013, to discuss ImmunoGen's financial results for
the three-month period and fiscal year ended June 30, 2013. Management
also will provide guidance for its fiscal year ending June 30, 2014 and
an update on the Company.
To access the live call by phone, dial 913-312-0836. Passcode: 4198948.
The call also may be accessed through the Investor Information section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through August 16, 2013.
ImmunoGen's presentation at the Wedbush 2013 Life Sciences Management
Access Conference on August 14, 2013 at 12:45 pm ET also will be
webcast. It will be accessible live through the Company's website as
described above, with a replay available for approximately one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
TAP technology uses a tumor-targeting monoclonal antibody to deliver one
of ImmunoGen's highly potent cancer-cell killing agents specifically to
tumor cells. Ten TAP compounds are now in the clinic, of which three are
wholly owned by the Company. The most advanced compound using
ImmunoGen's TAP technology, Kadcyla™, has been approved for marketing in
the US and Switzerland, and is undergoing regulatory review in the
European Union and Japan. Kadcyla is being commercialized in the US by
Genentech, a member of the Roche Group. More information about ImmunoGen
can be found at www.immunogen.com.
Kadcyla™ is a trademark of Genentech.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media